The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.
Freeburg NF, Chafamo D, Konanur Gopikrishna G, Murphy RM, Peng JJ, Parthasarathy S, Dumont S, Estrada EG, Logun MT, Sun Y, Wang X, Grover P, Rodriguez JL, Zhang DL, Park K, Fu Y, Ben Hamouda N, Hernandez-Verdin I, Lamrani L, Hicks KA, Cooper NA, Ekwegbara C, Bawden EG, Waterfall JJ, Fuentealba J, Alcantara M, Seykora JT, Prouty SM, Barrett D, Banerjee E, Cox A, Assenmacher CA, Macia C, Yin M, Carpenter EL, Ming GL, Sautès-Fridman C, Fridman WH, Tartour E, Wherry EJ, Amigorena S, Fraietta JA, Nasrallah MP, Song H, Miller TE, Bagley SJ, O'Rourke DM, Binder ZA, Alanio C, Silverbush D.
Freeburg NF, et al. Among authors: bagley sj.
Cell. 2026 Aug 20;189(17):5340-5358.e12. doi: 10.1016/j.cell.2026.05.026. Epub 2026 Jun 15.
Cell. 2026.
PMID: 42296961
Free PMC article.
Clinical Trial.